<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657172</url>
  </required_header>
  <id_info>
    <org_study_id>EYN-PRS-PI-31</org_study_id>
    <nct_id>NCT04657172</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults</brief_title>
  <acronym>VISION-1</acronym>
  <official_title>A Phase 3 Study of the Safety and Efficacy of 1% and 2% Pilocarpine Ophthalmic Solutions Administered With the Optejet® Microdose Dispenser for Temporary Improvement of Near Vision in Adults With Presbyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyenovia Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eyenovia Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Volunteer participants are evaluated for eligibility during a Screening Visit; those meeting&#xD;
      study inclusion/exclusion criteria are scheduled for 3 treatment visits. At each treatment&#xD;
      visit, 1 of the 3 study solutions is self-administered to both eyes. Afterwards, efficacy and&#xD;
      safety assessments are performed over a 3-hour period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Actual">March 26, 2021</completion_date>
  <primary_completion_date type="Actual">March 26, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects gaining ≥ 15 letters in mesopic, high contrast, binocular distance corrected near visual acuity (DCNVA)</measure>
    <time_frame>120 minutes post-dosing</time_frame>
    <description>The proportion of subjects gaining ≥ 15 letters in mesopic, high contrast, binocular DCNVA as compared to baseline.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Pilocarpine 1% Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1% pilocarpine ophthalmic solution administered with the Optejet dispenser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pilocarpine 2% Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% pilocarpine ophthalmic solution administered with the Optejet dispenser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo ophthalmic solution administered with the Optejet dispenser</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pilocarpine Ophthalmic</intervention_name>
    <description>Pilocarpine 1% or 2% ophthalmic solution administered with the Optejet microdose dispenser</description>
    <arm_group_label>Pilocarpine 1% Solution</arm_group_label>
    <arm_group_label>Pilocarpine 2% Solution</arm_group_label>
    <other_name>MicroLine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle ophthalmic solution administered with the Optejet microdose dispenser</description>
    <arm_group_label>Placebo Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria:&#xD;
&#xD;
          -  Poor near vision impacting daily living that requires near correction&#xD;
&#xD;
          -  Best-corrected distance visual acuity (BCDVA) of 0.0 logMar or better&#xD;
&#xD;
          -  Manifest refraction spherical equivalent ≥ -2.00 Diopters (D) and ≤ +2.00 D&#xD;
&#xD;
          -  Monocular DCNVA between 0.4 and 0.7 logMAR, inclusive&#xD;
&#xD;
        Primary Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of glaucoma or ocular hypertension&#xD;
&#xD;
          -  Narrow iridocorneal angles&#xD;
&#xD;
          -  History of intraocular surgery, refractive surgery, laser treatment, or iris surgery&#xD;
&#xD;
          -  Clinically significant abnormality of cornea, lens, retina, ciliary body, or iris&#xD;
&#xD;
          -  Presence/history of a severe/serious ocular condition or any other unstable medical&#xD;
             condition&#xD;
&#xD;
          -  Presence or history of manifest strabismus, amblyopia, or nystagmus&#xD;
&#xD;
          -  Current active eye disease for which topical or systemic ophthalmic medication is&#xD;
             necessary, except for dry eye syndrome managed using artificial tears&#xD;
&#xD;
          -  Clinically significant external ocular inflammation within 30 days of Screening Visit&#xD;
&#xD;
          -  Current use or history of rigid gas permeable (RGP) contact lens use within 30 days of&#xD;
             Screening Visit&#xD;
&#xD;
          -  Known pilocarpine allergy or contraindication to use of pilocarpine&#xD;
&#xD;
          -  Presence or history of congenital heart anomaly, valve disease, or other cardiac&#xD;
             disease&#xD;
&#xD;
          -  Disabling arthritis or limited motor coordination that would limit the subject's&#xD;
             ability to self-administer study solution using the Optejet&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsontcho (Sean) Ianchulev, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Eyenovia Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VISION-1 Study Site #21</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VISION-1 Study Site #52</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VISION-1 Study Site #54</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VISION-1 Study Site #53</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VISION-1 Study Site #50</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VISION-1 Study Site #17</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VISION-1 Study Site #22</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VISION-1 Study Site #51</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VISION-1 Study Site #03</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

